Navigation Links
China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
Date:3/1/2010

SHANGHAI, March 1 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics," the "Company") (Nasdaq: CHBT), the leading developer, manufacturer and distributor of probiotics products in China, today announced that its new bulk additive production facility has commenced commercial production in late February.

The new state-of-the-art production facility, located in Shanghai Qingpu Industrial Park, occupies a total of 54 acres of land with a 20,000 square-meter production area featuring a designed total production capacity of 150 tons annually and a world-class fermentation workshop equipped with sophisticated control system and customized design for its proprietary fermentation technology.

In late 2007, the Company began the construction of this facility. Upon completion of the building construction and equipment installation, testing and trial production started in July and October 2009, respectively. China-Biotics received its production permit from the local technology supervision bureau in early February 2010. The Company expects to produce 5 tons by the end of March, and the capacity utilization will gradually reach a run rate of 75 tons per year by December 2010.

Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics, commented, "We are very excited about the commencement of our Qingpu facility, with the advanced technology in probiotics production and large capacity. Our volume and quality can meet the demand from large institutional customers from both China and overseas markets. We believe the Qingpu facility will provide an additional engine of growth, beyond our widely acclaimed dietary supplement produced in our existing Pudong plant."

About China-Biotics

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company develops and produces its proprietary product portfolio including live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 15 and elsewhere in the Company's 2009 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward-looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

    For more information, please contact:

     Travis Cai
     Chief Financial Officer
     China-Biotics, Inc.
     Email: traviscai@chn-biotics.com

     Kevin Theiss
     Grayling
     Tel:   +1-646-284-9409
     Email: kevin.theiss@grayling.com

SOURCE China-Biotics, Inc.

Back to top

RELATED LINKS
http://www.chn-biotics.com

'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results
2. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter Fiscal 2010 Financial Results
3. China-Biotics, Inc. Appoints New Vice President
4. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
5. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
6. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
7. China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
8. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
9. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
10. China-Biotics, Inc. to Join Russell 3000 Index
11. China-Biotics, Inc. to Attend Digestive Disease Week 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):